In 2015 the U. S. Food and Drug Administration (FDA) approved ipilimumab, a monoclonal antibody (mAb) that blocks CTLA-4, to treat unresectable or metastatic melanoma (https://www.cancer.gov/about-cancer/treatment/drugs/fda-ipilimumab). The gene discussed is CTLA4; the disease is metastatic melanoma.